Tags : pibrentasvir

AbbVie’s Mavyret (glecaprevir/pibrentasvir) Receives FDA’s Approval for its Expanded Indication

Shots: The US FDA has granted approval to Mavyret for shortening the treatment duration from 12 to 8wks. in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes (GT1-6) The label expansion is based on P-IIIb EXPEDITION-8 study assessing Mavyret in treatment naïve, GT1-6 chronic HCV patients with compensated cirrhosis for 8wks., resulted […]Read More

AbbVie’s Maviret (glecaprevir/pibrentasvir) Receives European Commission Approval for Treatment-Naive Patients

Shots: The marketing authorization is based on P-IIIb EXPEDITION-8 study assessing Maviret in 280 treatment-naive chronic HCV patients with compensated cirrhosis across all major genotypes (GT1-6) for 8wks. The P-IIIb EXPEDITION-8 study resulted in @8wks. 97.9% GT1, 2, 4, 5 & 6 patients achieved a sustained virologic response 12wks. (SVR12); no case of virologic failures […]Read More